ReviewBiology direct2026
Decoding the Snail transcriptional network: its role in cancer progression and therapy.
Review in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The transcription factor Snail is a central regulatory hub that governs the transition from localized tumorigenesis to invasive, metastatic, therapy-resistant disease. Elucidating the mechanisms of Snail-driven epithelial-mesenchymal transition (EMT) and identifying strategies to target this pathway are critical challenges and promising frontiers for novel oncology therapeutics. In this review, we systematically analyzed the association between Snail expression and patient outcomes across multiple malignancies based on bioinformatics and statistical interrogation of clinical datasets and molecular interaction networks. Our findings indicate that Snail primarily exerts its oncogenic effects by directly activating a network of pro-metastatic and pro-survival oncogenes, rather than by repressing epithelial genes. We further show that the canonical E-box motif (CANNTG) is a poor predictor of Snail targets. Instead, Snail's tumor-promoting activity is largely mediated through its cooperation with EGR1/SP1 transcription factors on non-canonical TCACA promoter elements, which upregulate genes such as ZEB1, MMP9, and LEF1. Based on these conclusions, we propose a refined model for predicting Snail target genes. Finally, given that inhibiting the Snail-EMT axis presents a plausible opportunity to limit cancer progression and improve patient outcomes, we also discuss clinically relevant pharmacological strategies for targeting Snail.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.